You are here

Cell Targeting Peptides for Isolating Patient Specific Stem Cells

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43GM108198-01A1
Agency Tracking Number: R43GM108198
Amount: $224,911.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NIGMS
Solicitation Number: PA13-088
Timeline
Solicitation Year: 2014
Award Year: 2014
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
1301 Harbor Bay Parkway
ALAMEDA, CA 94502-2215
United States
DUNS: 781078977
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 DAVID LAROCCA
 (760) 815-2439
 dlarocca@biotimemail.com
Business Contact
 DAVID LAROCCA
Phone: (510) 521-3390
Email: dlarocca@biotimemail.com
Research Institution
 Stub
Abstract

DESCRIPTION (provided by applicant): The ability of human pluripotent stem cells (hPS) to both self-renew and differentiate into virtually any cell type make them a promising source of cells for drug research and development, toxicity screening, developmental research and cell based therapies. Indeed, the derivation of patient matched cells from induced pluripotent stem cells derived from patient skin samples has the potential to treat conditions where cells are lost to disease or injury. However, stem cellidentity, purity and scalability remain formidable challenges for translating pluripotent stem cell research to clinical applications. There is a lack of highly efficient methods for directed differentiation from hPS cell lines to mature cell types o interest and scale-up from hPS cells is costly. The derivation of scalable (self-renewing) embryonic progenitor stem cell lines offers a solution because they are well defined, clonally pure, simpler and less costly to produce on an industrial scale. Pre

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government